Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study

Acta Oncologica
Liisa HarjamaOuti Kuittinen

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare brain tumour with a dismal prognosis. Several phase II studies with high-dose methotrexate-based regimens have shown promising early results, but in all hospital-based data published so far, the disease outcome is poor. We performed a hospital-based retrospective analysis to evaluate the long-term results of the Nordic type of Bonn chemotherapy regimen in PCNSL patients. The study included 54 patients with newly diagnosed PCNSL who received chemotherapy with curative intent as their first-line treatment. We found promising response rates, 76% of the patients achieving CR and 22% patients achieving PR, with corresponding two-year EFS 53% and OS 76%. However, with longer follow-up a constant pattern of relapses was observed with only one patient remaining in primary remission after 60 months. The finding suggests that basic biological differences exist between PCNSL and systemic diffuse large B-cell lymphoma and there is a need for consolidation or maintenance therapy after achieving a remission in patients with PCNSL.

References

Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C SoussainV Leblond
Nov 5, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hendrik PelsUwe Schlegel
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lauren E AbreyUNKNOWN International Primary CNS Lymphoma Collaborative Group
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gaurav D ShahLauren E Abrey
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carole SoussainUNKNOWN Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lilyana AngelovEdward A Neuwelt
Sep 22, 2009·Lancet·Andrés J M FerreriUNKNOWN International Extranodal Lymphoma Study Group (IELSG)
Feb 10, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K FritschG Illerhaus
Mar 14, 2012·Best Practice & Research. Clinical Haematology·Andrés J M Ferreri, Emerenziana Marturano

❮ Previous
Next ❯

Citations

Mar 21, 2017·PloS One·Vesa KiviniemiJuha Voipio
Mar 1, 2017·Neuro-oncology Practice·Agnieszka KorfelTakanori Hirose
May 18, 2021·Frontiers in Oncology·Kaiyan TaoXin Tian
Sep 16, 2021·Current Oncology Reports·Kun-Wei Song, Tracy Batchelor

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.